Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: Additive effects of combination treatment on lipid regulation

Metabolism: Clinical and Experimental

Volumn 48, Issue 1, 1999, Pages 47-54

  Zambón, Daniel ^b   Ros, Emilio ^a   Rodriguez Villar, Camino ^b   Laguna, Juan Carlos ^b   Vázquez, Manuel ^b   Sanllehy, Carolina ^b   Casais, Elena ^b   Sol, Josep M ^b   Hernández, Gonzalo ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; FAMILIAL HYPERLIPEMIA; FEMALE; HUMAN; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032923831     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90009-4     Document Type: Article

References (62)

1. Goldstein JL, Schrott HG, Hazzard WR, et al: Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52:1544-1568, 1973
2. Grundy SM, Chait A, Brunzell JD: Familial Combined Hyperlipidemia Workshop. Arteriosclerosis 7:203-207, 1987
3. Genest JJ Jr, Martin-Munley SS, McNamara JR, et al: Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 85:2025-2033, 1992
4. Chait A, Albers JJ, Brunzell JD: Very low density lipoprotein overproduction in genetic forms of hypertriglyceridemia. Eur J Clin Invest 10:17-22, 1980
5. Jarvik GP, Brunzell JD, Austin MA, et al: Genetic predictors of FCHL in four large pedigrees. Influence of apoB level major locus predicted genotype and LDL subclass phenotype. Arterioscler Thromb 14:1687-1694, 1994
6. Bredie SJH, Demacker PNM, Stalenhoef AFH: Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low-density lipoprotein heterogeneity. Eur J Clin Invest 27:802-811, 1997
7. Wojciechowski AP, Farrall M, Cullen P, et al: Familial combined hyperlipidaemia linked to the apolipoprotein AI-CIII-AIV gene cluster on chromosome 11q23-q24. Nature 349:161-164, 1991
8. Babirak SP, Brown BG, Brunzell JD: Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler Thromb 12:1176-1183, 1992
9. Pajukanta P, Nuotio I, Terwilliger JD, et al: Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. Nat Genet 18:369-373, 1998
10. Kane JP, Havel RJ: Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins, in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic Basis of Inherited Disease (ed 8). New York, NY, McGraw-Hill, 1995, pp 1853-1885
11. Grundy SM, Vega GL: Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment. Arch Intern Med 152:28-34, 1992
12. Manninen V, Elo MO, Frick MH, et al: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260:641-651, 1988
13. Manninen V, Tenkanen L, Koskinen P, et al: Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment. Circulation 85:37-45, 1992
14. Drood JM, Zimetbaum PJ, Frishman WH: Nicotinic acid for the treatment of hyperlipoproteinemia. J Clin Pharmacol 31:641-650, 1991
15. Grundy SM: HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319:24-33, 1988
16. Grundy SM, Vega GL: Fibric acids: Effects on lipids and lipoprotein metabolism. Am J Med 83:9-20, 1987
17. The Expert Panel: Report of the National Cholesterol Education Program Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 148:36-69, 1988
18. The Expert Panel: Summary of the Second Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 269:3015-3023, 1993
19. National Institutes of Health Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease: Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 269:505-510, 1993
20. Study Group, European Atherosclerosis Society: Strategies for the prevention of coronary heart disease. A policy statement of the European Atherosclerosis Society. Eur Heart J 8:77-88, 1987
21. Carmena R, Ros E, Gómez-Gerique JA, et al: Recomendaciones para la prevention de la arteriosclerosis en España. Clin Invest Arterioscler 1:1-9, 1989
22. European Atherosclerosis Society: Prevention of coronary heart disease: Scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 2:113-156, 1992
23. Sociedad Española de Arteriosclerosis: Dieta y enfermedades cardiovasculares. Recomendaciones de la Sociedad Española de Arteriosclerosis. Clin Invest Arterioscler 6:43-61, 1994
24. Zambón D, Ros E, Casals E, et al: Effect of apolipoprotein E polymorphism on the serum lipid response to a hypolipidemic diet rich in monounsaturated fatty acids. Am J Clin Nutr 61:141-148, 1995
25. Bachorik PS, Alberts JJ: Precipitation methods for quantification of lipoproteins, in Alberts JJ (ed): Methods in Enzymology, vol 129. Orlando, FL, Academic, 1986, pp 78-100
26. Riepponen P, Marniemi J, Rautaoja T: Immunoturbidimetric determination of apolipoproteins A-I and B in serum. Scand J Clin Lab Invest 47:739-744, 1987
27. Seen S: Cross-over Trials in Clinical Research. Chichester, UK, Wiley, 1993, pp 31-69
28. Vega GL, Grundy SM: Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy. JAMA 264:2759-2763, 1990
29. Ojala JP, Helve E, Tikkanen MJ: Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil. Cardiology 77:39-49, 1990 (suppl 4)
30. Bredie SJH, de Bruin TWA, Demacker PNM, et al: Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol 75:348-353, 1995
31. Nestel P, Simons L, Barter P, et al: A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: Prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. Atherosclerosis 129:231-239, 1997
32. Tikkanen MJ, Laakso M, Ilmonen M, et al: Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. Diabetes Care 21:477-481, 1998
33. Havel RJ, Kane JP: Structure and metabolism of plasma lipoproteins, in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic Basis of Inherited Disease (ed 6). New York, NY, McGraw-Hill, 1989, pp 1129-1138
34. Ooi TC, Heinonen T, Alaupovic P, et al: Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: Comparison with fenofibrate. Arterioscler Thromb Vasc Biol 17:1793-1799, 1997
35. Gordon DJ, Probstfield JL, Garrison RJ, et al: High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. Circulation 79:8-15, 1989
36. Stampfer MJ, Sacks FM, Salvini S, et al: A prospective study of cholesterol, apolipoproteins and the risk of myocardial infarction. N Engl J Med 325:378-381, 1991
37. 3 subfractions, and the risk of acute myocardial infarction: A prospective population study in eastern Finnish men. Circulation 84:129-139, 1991
38. 3 cholesterol subfractions with the development of ischemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 90:769-774, 1994
39. Deckelbaum RJ, Granot E, Oschry Y, et al: Plasma triglyceride determines structure-composition in low and high density lipoproteins. Arteriosclerosis 4:225-231, 1984
40. Eisenberg S, Gavish D, Oschry Y, et al: Abnormalities in very low, low, and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment. J Clin Invest 74:470-482, 1984
41. Packard CJ, Munro A, Lorimer AR, et al: Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. J Clin Invest 74:2178-2192, 1984
42. Austin MA, Breslow JL, Hennekens CH, et al: Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:1917-1921, 1988
43. Vega GL, Grundy SM: Comparison of apolipoprotein B to cholesterol in low density lipoproteins of patients with coronary heart disease. J Lipid Res 25:580-592, 1984
44. de Graaf J, Hak-Lemmers H, Hectors MP, et al: Enhanced susceptibility to in vitro oxidation of dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 11:298-306, 1991
45. Pauciullo P, Marotta G, Rubba P, et al: Serum lipoproteins, apolipoproteins and very low density lipoprotein subfractions during 6-month fibrate treatment in primary hypertriglyceridemia. J Intern Med 228:425-430, 1990
46. Dachet C, Cavallero E, Martin C, et al: Effect of gemfibrozil on the concentration and composition of very low density and low density lipoproteins subfractions in hypertriglyceridemic patients. Atherosclerosis 113:1-9, 1995
47. Mantari M, Koskinen P, Manninen V, et al: Effect of gemfibrozil on the concentration and composition of plasma lipoproteins. Atherosclerosis 81:11-17, 1990
48. Hokanson JE, Austin MA, Zambon A, et al: Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb 13:427-434, 1993
49. Lahdenpera S, Tilly-Kiesi M, Vuorinen-Markkola H, et al: Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes. Diabetes Care 16:584-592, 1993
50. Yuan J, Tsai MY, Hunninghake DB: Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis 110:1-11, 1994
51. Ericsson CG, Hamsten A, Nilsson J, et al: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347:849-853, 1996
52. Gianturco SH, Bradley WA, Nozaki S, et al: Effects of lovastatin on the levels, structure, and atherogenicity of VLDL in patients with moderate hypertriglyceridemia. Arterioscler Thromb 13:472-481, 1993
53. Contacos C, Barter PJ, Sullivan DR: Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler Thromb 13:1755-1762, 1993
54. Zhao SP, Hollaar L, van't Hooft FM, et al: Effect of simvastatin on the apparent size of LDL particles in patients with type IIb hyperlipoproteinemia. Clin Chim Acta 203:109-118, 1991
55. Tilly-Kiesi M: The effect of lovastatin treatment on low-density lipoprotein hydrated density distribution and composition in patients with intermittent claudication and primary hypercholesterolemia. Metabolism 40:623-628, 1991
56. Berglund L: Diet and drug therapy for lipoprotein(a). Curr Opin Lipidol 6:48-56, 1995
57. Shepherd J: Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety. Eur Heart J 16:5-13, 1995
58. East C, Bilheimer DW, Grundy SM: Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med 109:25-32, 1988
59. Vega GL, Grundy SM: Management of primary mixed hyperlipidemia with lovastatin. Arch Intern Med 150:1313-1319, 1990
60. Glueck CJ, Oakes N, Speirs J, et al: Gemflbrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 70:1-9, 1992
61. Feher MD, Foxton J, Banks D, et al: Long-term safety of statin-flbrate combination treatment in the management of hypercholesterolemia in patients with coronary artery disease. Br Heart 174:14-17, 1995
62. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al: Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 80:608-613, 1997